



[Fig.1]




[Fig.2]




[Fig. 3] Confirmation of anti-mesothelin CAR expression

- (a) Non infection
- (b) VH07(15)VL07
- (c) VL07(15)VH07
- (d) VH07(25)VL07
- (e) VL07(25)VH07




[Fig. 4]


Expression level of Mesothelin




[Fig. 5]



[Fig. 6 A]



[Fig. 6B]



A498 only Well containing tumor only

FLS: PE

FSC-A, SSC-A subset
57.2%

Comp-BV105-A, SSC-A
84.0%

CD45

Co-culture VS A498 Co-culture well

1:1

Non infection

FSC-A, SSC-A subset
60.2%

Comp-BV105-A, SSC-A
7.33%

CD45

1:3

FSC-A, SSC-A subset
60.2%

Comp-BV105-A, SSC-A
18.3%

CD45

VH07(15)VL07

FSC-A, SSC-A subset
61.4%

Comp-BV105-A, SSC-A
0.94%

CD45

VH07(25)VL07

FSC-A, SSC-A subset
61.7%

Comp-BV105-A, SSC-A
2.38%

CD45


Peak of tumor cell
Peak of lymphocyte
including CAR-T cell

The figure displays flow cytometry data for ACC-MESO1 cells. On the left, a histogram shows the current response to PE-A and its subunit. The x-axis is labeled 'PE-A' with a logarithmic scale from 10^0 to 10^4 . The y-axis is labeled 'Current'. Two curves are shown: a solid line for 'PE-A subunit' and a dashed line for '89.1%'. The subunit curve is shifted to the right, indicating a higher current response.


On the right, three bar charts show the IFN-gamma concentration (pg/mL) for different conditions (a, b, c, d) at three ratios: 1:1, 1:3, and 1:5. The y-axis for all bar charts ranges from 0 to 1600 pg/mL. The conditions are: (a) Non infection, (b) VH07(15)VL07, (c) VH07(25)VL07, and (d) Tumor only.

Ratio	Condition	IFN-g conc. (pg/mL)
1:1	(a) Non infection	~0
	(b) VH07(15)VL07	~1550
	(c) VH07(25)VL07	~550
	(d) Tumor only	~0
1:3	(a) Non infection	~0
	(b) VH07(15)VL07	~1450
	(c) VH07(25)VL07	~500
	(d) Tumor only	~0
1:5	(a) Non infection	~0
	(b) VH07(15)VL07	~850
	(c) VH07(25)VL07	~250
	(d) Tumor only	~0


[Fig.7B]



[Fig.7C]




[Fig.8]




- (a) Non infection
- (b) VLMO(15)VHMO
- (c) VHMO(15)VLMO
- (d) VLMO(25)VHMO
- (e) VHMO(25)VLMO

[Fig.9]




[Fig.10]


Therapeutic effects of 7 $\times$ 19 metho CAR-T cells
in pre-established mouse solid tumor model




[Fig. 11]




[Fig.12A]



[Fig.12B]



[Fig. 13]



[Fig. 14]

